N. Schmitz

发表

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

A. Rosenwald, Y. Natkunam, R. Advani, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

N. Schmitz, R. Schlenk, H. Döhner, 2004, Blood.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

Sin-Ho Jung, Arnaud Jaccard, Tohru Murayama, 2016, The Lancet. Oncology.

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2019, The Lancet.

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.

N. Schmitz, E. Hoster, W. Hiddemann, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells

N. Schmitz, G. Wulf, J. Hasenkamp, 2009, Annals of Hematology.

Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.

N. Schmitz, P. Dreger, M. Michallet, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic blood stem cell transplantation: considerations for donors.

N. Schmitz, A. Gratwohl, D. Stroncek, 1997, Blood.

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.

N. Schmitz, H. Einsele, A. Ho, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of HLA-A*0201-presented T-cell epitopes derived from the tumor-associated antigen M-phase phosphoprotein II in patients with acute myeloid leukemia

N. Schmitz, D. Kabelitz, M. Zeis, 2010, Leukemia.

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

N. Schmitz, A. Hunter, C. Kyriakou, 2008 .

Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

V. Diehl, N. Schmitz, J. Franklin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, D. Blaise, E. Deconinck, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Paola Fazi, Marco Vignetti, Giuseppe Avvisati, 2013, The New England journal of medicine.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

N. Schmitz, R. Schlenk, A. Ganser, 2019, Leukemia.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

N. Schmitz, K. Döhner, R. Schlenk, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies

N. Schmitz, A. Sureda, 2003, Annals of Hematology.

R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome

N. Schmitz, A. Pettitt, N. Russell, 2009, Haematologica.

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, L. Kanz, N. Russell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma

N. Schmitz, A. Claviez, A. Sureda, 2008, Bone Marrow Transplantation.

The role of allogeneic stem‐cell transplantation in Hodgkin's disease

N. Schmitz, A. Sureda, 2005, European journal of haematology. Supplementum.

Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect

N. Schmitz, L. Trümper, P. Dreger, 2004, Bone Marrow Transplantation.

Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results.

N. Schmitz, A. Sureda, S. Robinson, 2004, Seminars in oncology.

Reply to K. Tay et al

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011 .

Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG).

V. Diehl, N. Schmitz, D. Hasenclever, 1995, Leukemia & lymphoma.

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.

N. Schmitz, M. Pfreundschuh, B. Lathan, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

N. Schmitz, S. Montoto, D. Blaise, 2021, Blood advances.

KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2022, The Lancet. Haematology.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

Cutaneous gamma/delta T‐cell lymphoma

N. Schmitz, E. Jaffe, C. Sander, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

transplantation lymphoma patients undergoing autologous peripheral blood stem cell

N. Schmitz, A. Hunter, G. Guillerm, 2011 .

Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.

N. Schmitz, A. Hunter, P. Biron, 2009, Blood.

Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

M. Ziepert, N. Schmitz, G. Salles, 2021, American journal of hematology.

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

N. Schmitz, C. Flowers, B. Coiffier, 2017, The oncologist.

Hematopoietic stem cell transplantation for hematological malignancies in Europe

N. Schmitz, A. Gratwohl, H. Baldomero, 2003, Leukemia.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia

N. Schmitz, W. Siegert, G. Gahrton, 1996, British journal of haematology.

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

N. Schmitz, M. Gramatzki, H. Wolf, 2015, British journal of haematology.

Autologous or allogeneic transplantation in B- and T-cell lymphomas.

N. Schmitz, M. Nickelsen, B. Glass, 2012, Best practice & research. Clinical haematology.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

N. Schmitz, G. Salles, J. Radford, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

N. Schmitz, P. Dreger, B. Glass, 2001, Annals of Hematology.

A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia.

N. Schmitz, P. Dreger, M. Kneba, 2000, Experimental hematology.

of the NHL-B2 trial of the DSHNHL the Treatment of Elderly Patients with Aggressive Lymphomas: Results 2-weekly or 3-weekly CHOP Chemotherapy with or without Etoposide for

N. Schmitz, A. Feller, M. Reiser, 2013 .

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL for the treatment of young patients with good-prognosis (normal LDH) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide

N. Schmitz, M. Pfreundschuh, D. Hasenclever, 2008 .

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Blood.

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.

N. Schmitz, M. Baudis, M. Pfreundschuh, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma

N. Schmitz, C. Pott, S. Dietrich, 2011, Cancer.

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis

N. Schmitz, G. Lenz, W. Berdel, 2021, Annals of Hematology.

Can corporatization contribute to quality assurance and cost control in the German hospital sector? A pilot project for stem cell transplantation.

N. Schmitz, R. Walshe, V. Diehl, 1999, Health policy.

Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality

N. Schmitz, K. Sullivan, P. Brooks, 1999, Bone Marrow Transplantation.

Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation

N. Schmitz, 2007 .

Transplantation of peripheral blood progenitor cells from HLA‐identical sibling donors

N. Schmitz, J. Garcia-conde, M. Labopin, 1996, British journal of haematology.

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

A. Rosenwald, M. Ziepert, N. Schmitz, 2010, Blood.

Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery

N. Schmitz, P. Dreger, N. Neuhoff, 1999, Bone Marrow Transplantation.

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

N. Schmitz, P. Dreger, D. Linch, 1996, The Lancet.

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation

N. Schmitz, D. Hasenclever, A. Nagler, 1998, Bone Marrow Transplantation.

Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease

N. Schmitz, P. Dreger, T. Klingebiel, 2004, Annals of Hematology.

Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma

N. Schmitz, P. Dreger, N. Neuhoff, 1998, Bone Marrow Transplantation.

Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)

N. Schmitz, E. Hoster, W. Hiddemann, 2016 .

Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy

N. Schmitz, G. Lenz, W. Berdel, 2021, Leukemia & lymphoma.

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.

N. Schmitz, H. Müller-Hermelink, H. Einsele, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, A. Hunter, C. Kyriakou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing engraftment--source and dose of stem cells.

N. Schmitz, J. Barrett, 2002, Seminars in hematology.

Consensus conferences : guidelines on malignant lymphoma . part 2 : marginal zone lymphoma , mantle cell lymphoma , peripheral T-cell lymphoma

N. Schmitz, E. Iannitto, P. Zinzani, 2013 .

High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia.

N. Schmitz, D. Kabelitz, R. Reimer, 2011, Leukemia research.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

N. Schmitz, H. Döhner, P. Paschka, 2013, Blood.

HYPOMAGNESAEMIA AND CYCLOSPORIN TOXICITY

N. Schmitz, H. Euler, J. Gosney, 1985, The Lancet.

Does hematopoietic stem cell transplantation improve patient outcome in juvenile myelomonocytic leukemia?

N. Schmitz, 2005, Nature Clinical Practice Oncology.

[Juvenile chronic leukemia and chronic myelomonocytic leukemia. Experiences with bone marrow transplantation in childhood in 5 cases].

N. Schmitz, T. Klingebiel, G. Ehninger, 1992, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde.

High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation

N. Schmitz, R. Marcus, D. Cunningham, 1999 .

Differences between graft product and donor side effects following bone marrow or stem cell donation

N. Schmitz, M. Beksac, A. Nagler, 2003, Bone Marrow Transplantation.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Blood.

Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.

C. Rübe, M. Ziepert, N. Schmitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, D. Niederwieser, K. Indrák, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.

N. Schmitz, C. Kyriakou, G. Kobbe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

N. Schmitz, A. Sureda, S. Robinson, 2008 .

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

N. Schmitz, S. Montoto, T. A. Lister, 2007, Leukemia.

Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation.

N. Schmitz, P. Dreger, A. Zander, 1996, Blood.

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

N. Schmitz, H. Döhner, M. Hallek, 2008, Leukemia.

malignancies antigen-immature laminin receptor for the treatment of hematologic Induction of cytotoxic T-cell responses against the oncofetal

N. Schmitz, D. Kabelitz, A. Wagner, 2013 .

Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies

N. Schmitz, P. Dreger, D. Kabelitz, 2006, The Journal of Immunology.

Patients with Hematological Malignancies Antigen-Immature Laminin Receptor Protein Cell Epitopes Derived from the Oncofetal Identification of HLA-A * 0201-Presented T

N. Schmitz, P. Dreger, D. Kabelitz, 2006 .

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.

N. Schmitz, D. Kabelitz, A. Wagner, 2003, Blood.

Is there a graft‐versus‐leukaemia effect in the absence of graft‐versus‐host disease in patients undergoing bone marrow transplantation for acute leukaemia?

N. Schmitz, F. Mandelli, M. Labopin, 2000, British journal of haematology.

Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2018, British journal of haematology.

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation

N. Schmitz, P. Reimer, B. Metzner, 2016, Blood Cancer Journal.

CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2013, Annals of Hematology.

Prognostic factors in COPP-treated patients with Hodgkin's disease

N. Schmitz, H. Löffler, W. Gassmann, 1982, Blut: Zeitschrift für die Gesamte Blutforschung.

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.

N. Schmitz, R. Marcus, D. Cunningham, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PBSC collection from family donors in Japan: a prospective survey

N. Schmitz, H. Dohy, K. Kawa, 2014, Bone Marrow Transplantation.

Allogeneic transplantation of peripheral blood stem cells.

N. Schmitz, P. Dreger, 1999, Bailliere's best practice & research. Clinical haematology.

A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany.

N. Schmitz, R. Walshe, V. Diehl, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.

N. Schmitz, T. Haferlach, P. Dreger, 1993, British Journal of Cancer.

R andomized S tudy t o E valuate t he U se o f H igh-Dose T herapy as P art o f P rimary T reatment f or " Aggressive" L ymphoma

N. Schmitz, M. Baudis, M. Pfreundschuh, 2002 .

6. Report on Workshop: EBMT Workshop “High dose therapy in aggressive NHL”

N. Schmitz, 2001, Annals of Hematology.

The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.

Bingshu E. Chen, N. Schmitz, C. Gisselbrecht, 2020, Blood advances.

Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Suboptimal dosing of rituximab in male and female patients with DLBCL.

N. Schmitz, M. Pfreundschuh, M. Wiesen, 2014, Blood.

Non-Hodgkin Lymphoma Study Group (DSHNHL) of patients treated in the RICOVER-60 trial of the German High-Grade modern chemotherapy (CHOP-14) with or without rituximab: an analysis CNS events in elderly patients with aggressive lymphoma treated with

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2013 .

Severe events in donors after allogeneic hematopoietic stem cell donation

N. Schmitz, A. Gratwohl, H. Baldomero, 2009, Haematologica.

Allogeneic transplantation of peripheral blood progenitor cells.

N. Schmitz, H. Link, L. Arseniev, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.

N. Schmitz, M. Beksac, A. Nagler, 2005, Haematologica.

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

E. Kimby, N. Schmitz, S. Montoto, 2021, Bone Marrow Transplantation.

High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, G. Kobbe, W. Arcese, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma

N. Schmitz, A. Sureda, O. Servitje, 2008, Bone Marrow Transplantation.

The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas

N. Schmitz, H. Müller-Hermelink, W. Schmidt, 2005, British journal of haematology.

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

N. Schmitz, D. Blaise, H. Greinix, 2003, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease

N. Schmitz, A. Leha, M. Pfreundschuh, 2018, Bone Marrow Transplantation.

The role of allogeneic stem cell transplantation in T-cell lymphoma

N. Schmitz, M. Stelljes, B. Friedrichs, 2018, Current opinion in oncology.

Allogeneic transplantation in T-cell lymphomas.

N. Schmitz, B. Glass, Huei-Shan Wu, 2014, Seminars in hematology.

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation.

N. Schmitz, G. Dini, S. Mackinnon, 2009, Blood.

Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

N. Schmitz, C. Gisselbrecht, P. Colombat, 2010 .

Treatment of refractory Hodgkin's disease with high‐dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group

V. Diehl, N. Schmitz, W. Hiddemann, 1990, Cancer.

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT

N. Schmitz, A. Rohatiner, G. Meloni, 1999, British journal of haematology.

leukaemia: a chance for cure?

N. Schmitz, P. Dreger, N. von Neuhoff, 2022 .

The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia.

N. Schmitz, P. Dreger, 1997, Leukemia.

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.

N. Schmitz, G. Brittinger, H. Döhner, 2012, Blood.

The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?

N. Schmitz, P. Dreger, M. Kneba, 2005, Leukemia.

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

E. Kimby, N. Schmitz, H. Tilly, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases

N. Schmitz, G. Ehninger, U. Platzbecker, 2003, Annals of Hematology.

German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells

N. Schmitz, H. Einsele, W. Friedrich, 1997, Bone Marrow Transplantation.

Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.

N. Schmitz, A. Ho, S. Dietrich, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

N. Schmitz, A. Krämer, A. Ho, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.

N. Schmitz, T. Haferlach, S. Schnittger, 2013, Leukemia research.

Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience.

N. Schmitz, J. Garcia-conde, M. Labopin, 1996, Bone marrow transplantation.

Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes.

N. Schmitz, T. D. de Witte, H. Löffler, 1992, Seminars in hematology.

A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.

A. Rosenwald, M. Ziepert, N. Schmitz, 2020, Haematologica.

Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes.

N. Schmitz, H. Löffler, W. Gassmann, 1992, Hematology/oncology clinics of North America.

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingd

N. Schmitz, S. Kvaløy, H. Holte, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.

N. Schmitz, P. Dreger, N. von Neuhoff, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony‐stimulating factor and interleukin 2 in a myeloma model

N. Schmitz, J. Stritzke, J. Steinmann, 2003, British journal of haematology.

Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice

N. Schmitz, J. Steinmann, L. Uharek, 2001, Bone Marrow Transplantation.

Advances in the Treatment of Secondary CNS Lymphoma.

N. Schmitz, Huei-Shan Wu, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

N. Schmitz, A. Krämer, K. Kreuzer, 2010 .

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

D. Weisenburger, J. Armitage, J. Vose, 2017 .

G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.

N. Schmitz, P. Dreger, V. Eckstein, 1995, Experimental hematology.

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis

N. Schmitz, G. Lenz, E. Shumilov, 2022, Cancers.

The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.

N. Schmitz, N. Kröger, R. Parwaresch, 2000, The hematology journal : the official journal of the European Haematology Association.

Allogeneic peripheral blood progenitor cells: current status and future directions.

N. Schmitz, P. Dreger, B. Glass, 1996, Journal of hematotherapy.

THE PLACE OF BLOOD STEM CELLS IN ALLOGENEIC TRANSPLANTATION

N. Schmitz, N. Russell, A. Gratwohl, 1996, British journal of haematology.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

N. Schmitz, H. Einsele, A. Ho, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

V. Diehl, N. Schmitz, R. Marcus, 2004, Bone Marrow Transplantation.

Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

N. Schmitz, W. Siegert, H. Einsele, 2001, Annals of Hematology.

Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells.

N. Schmitz, L. Uharek, M. Zeis, 2000, Blood.

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT).

N. Schmitz, A. Gratwohl, J. Goldman, 1996, Bone marrow transplantation.

Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment

N. Schmitz, P. Dreger, D. Linch, 2002, Leukemia & lymphoma.

Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.

N. Schmitz, T. Haferlach, P. Dreger, 1995, Blood.

Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).

N. Schmitz, A. Zander, A. Gratwohl, 2005, Haematologica.

Recurrence of acute lymphoblastic leukemia in donor cells after allogeneic marrow transplantation associated with a deletion of the long arm of chromosome 6.

N. Schmitz, G. Schmidt, H. Löffler, 1987, Blood.

Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity

N. Schmitz, B. Glass, L. Uharek, 1999, Cancer Immunology, Immunotherapy.

Anti-CD25 antibody-drug conjugates: improving the delivery of death to lymphoma cells?

N. Schmitz, G. Lenz, 2021, The Lancet. Haematology.

CNS Disease In Younger Patients (

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2010 .

Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.

N. Schmitz, B. Glass, J. Steinmann, 2001, The hematology journal : the official journal of the European Haematology Association.

Peripheral Blood Stem Cells for Allogeneic Transplantation

N. Schmitz, P. Dreger, B. Glass, 2000 .

G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft

N. Schmitz, T. Haferlach, P. Dreger, 1994, British journal of haematology.

results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in

N. Schmitz, M. Hallek, S. Stilgenbauer, 2011 .

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

N. Schmitz, H. Döhner, M. Hallek, 2010, Blood.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial

N. Schmitz, H. Döhner, M. Hallek, 2010 .

Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2014 .

Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice

N. Schmitz, P. Dreger, B. Glass, 1997, British journal of haematology.

Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)

N. Schmitz, T. Haferlach, N. Russell, 1995, Blood.

Amplification of a Y‐chromosomal DNA sequence by the polymerase chain reaction for documentation of residual recipient cells in small samples from bone marrow, peripheral blood and cerebrospinal fluid after bone marrow transplantation

N. Schmitz, P. Dreger, A. Claviez, 1993, Electrophoresis.

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

N. Schmitz, H. Einsele, N. Kröger, 2009 .

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)

N. Schmitz, H. Einsele, N. Kröger, 2003, Bone Marrow Transplantation.

Therapy‐associated genetic aberrations in patients treated for non‐Hodgkin lymphoma

N. Schmitz, J. Basecke, F. Griesinger, 2008, British journal of haematology.

Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation.

N. Schmitz, W. Mueller-Ruchholtz, H. Löffler, 1988, Blood.

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

N. Schmitz, H. Einsele, A. Krämer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2008 .

Dose-Dense Rituximab Improves Outcome of Elderly Patients with Poor-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2007 .

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2016, Annals of Hematology.

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

N. Schmitz, P. Dreger, G. Wulf, 2009 .

Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease.

N. Schmitz, A. Sureda, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute monocytic leukemia with translocation t(1;11) (p31;q23): simultaneous staining of chromosomes and cell surface antigens.

N. Schmitz, B. Schlegelberger, S. Bödewadt-Radzun, 1990, Haematology and blood transfusion.

High‐dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential

N. Schmitz, A. Erbersdobler, B. Glass, 1991, British journal of haematology.

Allogeneic transplantation of blood stem cells: Coming of age?

N. Schmitz, P. Dreger, 2001, Annals of Hematology.

Developments in allogeneic peripheral blood progenitor cell transplantation.

N. Schmitz, N. Russell, A. Gratwohl, 1998, British journal of haematology.

Allogeneic peripheral blood progenitor cell transplantation in a murine model : Evidence for an improved graft-versus-leukemia effect

N. Schmitz, P. Dreger, B. Glass, 1997 .

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998

N. Schmitz, A. Gratwohl, J. Goldman, 1998, Bone Marrow Transplantation.

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series

N. Schmitz, K. Döhner, R. Schlenk, 2014 .

Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases

N. Schmitz, R. Champlin, J. Rizzo, 2001, Bone Marrow Transplantation.

The effects of rituximab treatment during pregnancy on a neonate.

N. Schmitz, M. Tiemann, H. Salwender, 2006, Haematologica.

Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type.

N. Schmitz, T. Haferlach, B. Schlegelberger, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Philadelphia chromosome (Ph) positive chronic myelocytic leukemia (CML): frequency of additional findings.

N. Schmitz, E. Gödde‐Salz, H. Bruhn, 1985, Cancer genetics and cytogenetics.

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

A. Rosenwald, M. Ziepert, W. Klapper, 2022, HemaSphere.

Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems

N. Schmitz, U. Paulus, P. Dreger, 1997, Stem cells.

Reply to C. Fozza.

N. Schmitz, P. Dreger, A. Goldstone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003.

N. Schmitz, E. Thiel, M. Griesshammer, 2008 .

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

N. Schmitz, C. Craddock, K. Peggs, 2008 .

Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC

N. Schmitz, P. Dreger, M. Kneba, 2000, Bone Marrow Transplantation.

Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial.

N. Schmitz, D. Hasenclever, N. Russell, 2010, The Lancet. Oncology.

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

N. Schmitz, E. Montserrat, J. Klein, 2000, Blood.

Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.

N. Schmitz, J. Klein, A. Gratwohl, 2006, Blood.

PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations.

N. Schmitz, P. Dreger, K. Oberböster, 1996, Bone marrow transplantation.

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

A. Rosenwald, N. Schmitz, P. Gaulard, 2010 .

Staging systems for multiple myeloma: a comparison

N. Schmitz, T. Haferlach, H. Löffler, 1985, British journal of haematology.

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

Michael Hummel, Markus Loeffler, Peter Möller, 2010, Blood.

German High-Grade Non-Hodgkin Lymphoma Study Group analysis of patients with T-cell lymphoma treated in studies of the Treatment and prognosis of mature T-cell and NK-cell lymphoma: an

Markus Loeffler, Anthony D. Ho, Norbert Schmitz, 2013 .

Allogeneic transplantation in lymphoma: current status

N. Schmitz, P. Dreger, B. Glass, 2007, Haematologica.

Nodale aggressive Non-Hodgkin-Lymphome

N. Schmitz, M. Engelhard, L. Trümper, 2006 .

Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study.

N. Schmitz, H. Müller-Hermelink, T. Rüdiger, 2004, The hematology journal : the official journal of the European Haematology Association.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Dirk Hasenclever, Markus Loeffler, Christian Rübe, 2004, Blood.

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.

N. Schmitz, G. Lenz, M. Stelljes, 2018, Blood.

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

N. Schmitz, J. Radford, C. Gisselbrecht, 2017, Bone Marrow Transplantation.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

N. Schmitz, G. Salles, J. Radford, 2016, Bone Marrow Transplantation.

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

N. Schmitz, H. Einsele, G. Dini, 2002, Bone Marrow Transplantation.

Treatment of relapsed or refractory adult acute lymphocytic leukemia

N. Schmitz, E. Thiel, W. Hiddemann, 1992, Cancer.

hydroxyurea in chronic myelogenous leukemia . The German CML Randomized comparison of interferon-alpha with busulfan and

N. Schmitz, H. Heimpel, L. Kanz, 2002 .

Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia

N. Schmitz, H. Heimpel, L. Kanz, 2002 .

ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG

N. Schmitz, R. Schlenk, H. Döhner, 2012 .

Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia12

Sandra Siegel, Norbert Schmitz, N. Schmitz, 2008, The Journal of Immunology.

Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia 1 , 2

N. Schmitz, M. Tiemann, D. Kabelitz, 2008 .

Induction of antitumour immunity using survivin peptide‐pulsed dendritic cells in a murine lymphoma model

N. Schmitz, A. Wagner, M. Zeis, 2003, British journal of haematology.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

N. Schmitz, H. Einsele, A. Ho, 2014, Leukemia.

Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.

N. Schmitz, B. Hertenstein, F. Brix, 1988, Blood.

Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.

N. Schmitz, B. Hertenstein, F. Brix, 1988, Blood.

Autologous stem cell transplantation in lymphoma.

N. Schmitz, C. Buske, C. Gisselbrecht, 2007, Seminars in hematology.

TP53 mutation and survival in aggressive B cell lymphoma

A. Rosenwald, W. Klapper, N. Schmitz, 2017, International journal of cancer.

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

A. Rosenwald, M. Ziepert, W. Klapper, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Tuan S. Nguyen, N. Schmitz, Sonali M. Smith, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Markus Loeffler, Anthony Ho, Norbert Schmitz, 2008, The Lancet. Oncology.

Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies

Sandra Siegel, Norbert Schmitz, N. Schmitz, 2006, Leukemia & lymphoma.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

N. Schmitz, R. Siebert, H. Döhner, 2007, Leukemia.

Two cases of graft-versus-host disease following transfusion of nonirradiated blood products

N. Schmitz, H. Löffler, W. Gassmann, 1982, Blut.

Acute eosinophilic leukemia: characterization by cytochemistry, chromosomal analysis, and in vitro colony formation

N. Schmitz, H. Löffler, W. Gassmann, 1985, Klinische Wochenschrift.

Acute myelomonocytic leukemia with involvement of eosinophils and inversion of chromosome 16

N. Schmitz, H. Löffler, W. Gassmann, 1984, Blut: Zeitschrift für die Gesamte Blutforschung.

Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02)

N. Schmitz, J. Cayuela, H. Dombret, 2014 .

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

D. Weisenburger, J. Vose, N. Schmitz, 2003, British journal of haematology.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

A. Rosenwald, M. Ziepert, N. Schmitz, 2012, The Lancet. Oncology.

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation

N. Schmitz, A. Ganser, D. Blaise, 2015, Leukemia & lymphoma.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

N. Schmitz, W. Hiddemann, M. Boccadoro, 2005, Blood.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

N. Schmitz, J. Gerss, T. Brümmendorf, 2016, Leukemia.

ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients

N. Schmitz, C. Buske, M. Pfreundschuh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

V. Diehl, N. Schmitz, J. Franklin, 1998, Blood.

Salvage Therapy of Adult ALL

N. Schmitz, E. Thiel, W. Hiddemann, 1996 .

Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).

N. Schmitz, E. Hoster, W. Hiddemann, 2008 .

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

V. Diehl, N. Schmitz, W. Hiddemann, 2004, Blood.

Generation of Cytotoxic Responses in Mice and Human Individuals Against Hematological Malignancies Using Survivin-RNA-Transfected Dendritic Cells1

N. Schmitz, P. Dreger, D. Kabelitz, 2003, Journal of Immunology.

Survivin-RNA-Transfected Dendritic Cells Hematological Malignancies Using and Human Individuals Against Generation of Cytotoxic Responses in Mice

N. Schmitz, P. Dreger, D. Kabelitz, 2003 .

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2009, Blood.

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.

A. Rosenwald, M. Ziepert, N. Schmitz, 2021, The Lancet. Haematology.

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma

Y. S. Lee, N. Schmitz, F. d'Amore, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT)

N. Schmitz, G. Dini, A. Gratwohl, 2005, Bone Marrow Transplantation.

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.

N. Schmitz, A. Ho, C. Pott, 2007, Haematologica.

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

N. Schmitz, D. Hasenclever, A. Nagler, 2002, Blood.

High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease

N. Schmitz, T. Haferlach, P. Dreger, 1993, Annals of Hematology.

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.

P. Bierman, J. Vose, N. Schmitz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasmapheresis in paraproteinemia

N. Schmitz, H. Euler, H. Löffler, 1985, Blut.

Danazol in acquired amegakaryocytic thrombocytopenic purpura: A case report

N. Schmitz, H. Euler, H. Löffler, 1985, Blut.

N. Schmitz, S. Kvaløy, H. Holte, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter]

N. Schmitz, T. Haferlach, P. Dreger, 1993 .

Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.

N. Schmitz, T. Haferlach, P. Dreger, 1993, Blood.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Dirk Hasenclever, Markus Sieber, Norbert Schmitz, 2002, The Lancet.

Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?

N. Schmitz, F. Mandelli, M. Labopin, 2000 .

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy

N. Schmitz, H. Johnsen, N. Russell, 2008, Haematologica.

Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy.

N. Schmitz, P. Dreger, B. Glass, 1997, International journal of hematology.

Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation

N. Schmitz, S. Montoto, S. Dietrich, 2019, Bone Marrow Transplantation.

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.

N. Schmitz, B. Hillner, T. Smith, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standards for blood and marrow progenitor cell processing, collection and transplantation

N. Schmitz, A. Gratwohl, J. Goldman, 2000 .

Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor After Autologous Bone Marrow Transplantation

N. Schmitz, K. Welte, S. Burdach, 1990 .

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party

N. Schmitz, N. Russell, A. Tichelli, 2008 .

Selective antilymphocyte sera (SAL) in bone marrow transplantation. I. In vitro characterization of antihuman SAL and the development of absorption procedures using cultured cell lines.

N. Schmitz, H. Müller-Hermelink, M. Anderson, 1985, International archives of allergy and applied immunology.

Peripheral Blood Progenitor Grafts Obtained from Healthy Donors

N. Schmitz, P. Dreger, 1997 .

Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.

N. Schmitz, P. Dreger, H. Löffler, 1993, Leukemia.

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

N. Schmitz, W. Friedrich, A. Gratwohl, 2002, Bone Marrow Transplantation.

Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model

N. Schmitz, P. Dreger, B. Glass, 2003, Bone Marrow Transplantation.

Allogeneic Bone Marrow Transplantation for Childhood Acute Lymphoblastic Leukemia in Second Remission After Intensive Primary and Relapse Therapy

N. Schmitz, W. Siegert, W. Friedrich, 2003 .

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

J. Armitage, N. Schmitz, A. Hagenbeek, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.

J. Armitage, N. Schmitz, A. Hagenbeek, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytogenetic studies on recipients of allogeneic bone marrow transplants after fractionated total body irradiation

N. Schmitz, H. Löffler, E. Gödde‐Salz, 1985, British journal of haematology.

Higher than expected transplant-related mortality and relapse following nonmyeloablative stem cell transplantation for lymphoma adversely effects progression free survival.

N. Schmitz, N. Russell, S. Mackinnon, 2000 .

Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT)

N. Schmitz, B. Glass, J. Steinmann, 1998 .

CD48 monoclonal antibody K31 for bone marrow transplantation.

N. Schmitz, P. Dreger, V. Eckstein, 1992, Progress in clinical and biological research.

Lymphohaematopoietic chimaerism after bone marrow transplantation for chronic myeloid leukaemia: results of simultaneous cytogenetic analyses on T‐cell colonies, myeloid, and erythroid progenitor cells

N. Schmitz, B. Schlegelberger, H. Löffler, 1991, British journal of haematology.

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

N. Schmitz, M. Pfreundschuh, P. Dreger, 2014, The Lancet. Oncology.

Conservative Management of Gastric Lymphoma: the Treatment Option of Choice

N. Schmitz, W. Schmidt, R. Sonnen, 2004, Leukemia & lymphoma.

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

N. Schmitz, A. Ganser, R. Brand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia

N. Schmitz, G. Ehninger, M. Schaich, 2013, British journal of haematology.

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.

N. Schmitz, H. Döhner, S. Stilgenbauer, 2004, Blood.

Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers

N. Schmitz, B. Weiss, M. Uppenkamp, 2003, Annals of Hematology.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

R. Greil, H. Eich, V. Diehl, 2017, The Lancet.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

N. Schmitz, P. Dreger, G. Kobbe, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party

N. Schmitz, D. Blaise, P. Dreger, 2014, Leukemia.

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

A. Rosenwald, R. Greil, M. Ziepert, 2020, Leukemia.

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

A. Rosenwald, M. Ziepert, W. Klapper, 2013, Blood.

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Dirk Hasenclever, Markus Loeffler, Norbert Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

N. Schmitz, M. Dreyling, A. Josting, 2006, British journal of haematology.

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

N. Schmitz, E. Campo, E. Iannitto, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

A. Rosenwald, N. Schmitz, P. Gaulard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

A. Rosenwald, R. Gascoyne, N. Schmitz, 2018, Blood.

How I manage peripheral T‐cell lymphoma, not otherwise specified and angioimmunoblastic T‐cell lymphoma: current practice and a glimpse into the future

N. Schmitz, L. Leval, 2017, British journal of haematology.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

N. Schmitz, C. Buske, M. Pfreundschuh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?

N. Schmitz, K. Savage, M. Nickelsen, 2016, Hematology/oncology clinics of North America.

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

R. Gascoyne, M. Ziepert, N. Schmitz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

R. Gascoyne, M. Ziepert, N. Schmitz, 2014 .

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Michael Hallek, Ulrich Keller, Mathias Witzens-Harig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group.

N. Schmitz, M. Pfreundschuh, L. Trümper, 2012 .

Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.

N. Schmitz, C. Gisselbrecht, M. Bargetzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

A. Rosenwald, M. Ziepert, W. Klapper, 2015, Leukemia.

Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL Running title: OUTCOME PREDICTION IN DLBCL

Marita, A. Rosenwald, N. Schmitz, 2010 .

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

N. Schmitz, E. Hoster, W. Hiddemann, 2008 .

Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario

N. Schmitz, G. Lenz, E. Shumilov, 2022, Cancers.

Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006 .

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

N. Schmitz, N. Russell, S. Mackinnon, 2002, Blood.

[Aggressive B-cell lymphoma: modern diagnostics and treatment].

N. Schmitz, H. S. Wu, B. Glass, 2014, Deutsche medizinische Wochenschrift.

Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation

N. Schmitz, T. Haferlach, P. Dreger, 1997, Bone Marrow Transplantation.

Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study.

N. Schmitz, S. Montoto, A. Rohatiner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).

N. Schmitz, P. Dreger, B. Glass, 1998, Experimental hematology.

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

C. Rübe, N. Schmitz, H. Einsele, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

N. Schmitz, H. Döhner, M. Hallek, 2017, Blood.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

N. Schmitz, P. Dreger, G. Wulf, 2008 .

The Role of Allogeneic Stem Cell Transplantation in Hodgkin’s Lymphoma

N. Schmitz, P. Dreger, E. Doménech, 2014, Current Treatment Options in Oncology.

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.

N. Schmitz, T. Lister, A. Norton, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.

N. Schmitz, A. Ganser, R. Brand, 2007 .

Elimination of minimal residual disease in chronic lymphocytic leukemia using allogeneic stem cell transplantation

N. Schmitz, H. Döhner, S. Stilgenbauer, 2009 .

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. Ziepert, N. Schmitz, C. Flowers, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia

N. Schmitz, S. Schnittger, W. Kern, 2015 .

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

N. Schmitz, H. Einsele, A. Krämer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma

N. Schmitz, J. Steinmann, L. Uharek, 2002, British journal of haematology.

Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL

N. Schmitz, U. Paulus, P. Dreger, 1997, Bone Marrow Transplantation.

DEXA-BEAM Salvage Chemotherapy and High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation in Hodgkin’s Disease

V. Diehl, N. Schmitz, M. Pfreundschuh, 1994 .

M-Phase Phosphoprotein 11 Is a Highly Immunogenic Tumor Antigen in Patients with Acute Myeloid Leukemia

N. Schmitz, M. Schweizer, M. Zeis, 2012, Acta Haematologica.

Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1 -Mutations and High or Low Ratio FLT3-ITD s

N. Schmitz, H. Einsele, W. Berdel, 2017 .

International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.

M. Ziepert, N. Schmitz, G. Salles, 2020, Blood.

Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia

N. Schmitz, P. Dreger, M. Kneba, 1999, British journal of haematology.

Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect.

N. Schmitz, P. Dreger, B. Glass, 1997, Blood.

THE ROLE OF THE SPLEEN AFTER BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS

N. Schmitz, M. Tiemann, B. Schlegelberger, 1992, British journal of haematology.

Blood and Bone Marrow Transplantation analysis from the Lymphoma Working Party of the European Group for an following reduced intensity allogeneic progenitor cell transplantation: Chemoresistant or aggressive lymphoma predicts for a poor outcome

N. Schmitz, N. Russell, S. Mackinnon, 2013 .

Stem Cell Mobilization in Healthy Donors: Current Status

N. Schmitz, P. Dreger, 1999, Transfusion Medicine and Hemotherapy.

Bone marrow transplantation in childhood leukemia in West Germany.

N. Schmitz, G. Ehninger, G. Wündisch, 1987, Haematology and blood transfusion.

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

N. Schmitz, H. Döhner, P. Paschka, 2012 .

Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT

N. Schmitz, S. Montoto, P. Dreger, 2020, Bone Marrow Transplantation.

Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial

N. Schmitz, G. Ehninger, W. Aulitzky, 2011, Leukemia.

Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia.

N. Schmitz, P. Dreger, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Diffuse Large B-Cell Lymphoma

N. Schmitz, A. Bazarbachi, M. Stelljes, 2018, The EBMT Handbook.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice

N. Schmitz, J. Steinmann, L. Uharek, 2002, Bone Marrow Transplantation.

Treatment results of aggressive B non‐Hodgkin's lymphoma in advanced age considering comorbidity

N. Schmitz, W. Schmidt, R. Kuse, 2002, British journal of haematology.

Immunotherapeutic aspects of allogeneic peripheral progenitor cells.

N. Schmitz, P. Dreger, M. Krönke, 1998, Bone marrow transplantation.

Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial

N. Schmitz, G. Ehninger, M. Schaich, 2010 .

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2010 .

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

N. Schmitz, N. Kröger, S. Iacobelli, 2016, Annals of Hematology.

The Impact of Disease Status at Transplant and Time to First Relapse on Outcome in Children and Adolescents with Hodgkin’s Lymphoma Undergoing Autologous Stem Cell Transplantation.

N. Schmitz, B. Hero, F. Zintl, 2004 .

Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease.

N. Schmitz, P. Ljungman, O. Ringdén, 1995, Bone marrow transplantation.

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.

N. Schmitz, P. Dreger, G. Ehninger, 1995, Bone marrow transplantation.

Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.

A. Rosenwald, M. Ziepert, N. Schmitz, 2017 .

Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.

V. Diehl, N. Schmitz, H. Döhner, 2006, Haematologica.

ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients

A. Rosenwald, D. Weisenburger, J. Armitage, 2019, Haematologica.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations

N. Schmitz, H. Einsele, A. Krämer, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Obesity negatively impacts outcome in elderly female patients with aggressive B‐cell lymphomas treated with R‐CHOP : results from prospective trials of the German high grade non‐Hodgkin's lymphoma trial group

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2018, British journal of haematology.

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2007 .

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

N. Schmitz, H. Döhner, M. Hallek, 2009 .

Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation.

N. Schmitz, A. Sureda, S. Robinson, 2004 .

Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT

N. Schmitz, P. Dreger, A. Claviez, 2000, Bone Marrow Transplantation.

Mature T-cell lymphoma patients show high relapse rates after high dose therapy followed by autologous transplantation

N. Schmitz, M. Nickelsen, B. Glass, 2008 .

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

N. Schmitz, N. Klopp, T. Illig, 2013, Leukemia.

Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes

N. Schmitz, P. Dreger, J. Steinmann, 2004, Leukemia.

The impact of SOCS1 mutations in diffuse large B‐cell lymphoma

A. Rosenwald, M. Ziepert, W. Klapper, 2019, British journal of haematology.

Dose-dense chemotherapy in breast cancer and lymphoma.

N. Schmitz, C. Hudis, 2004, Seminars in oncology.

Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma

R. Spang, A. Rosenwald, M. Ziepert, 2020, Leukemia & lymphoma.

Standard of Care in First-Line Therapy of DLBCL

N. Schmitz, F. Frontzek, G. Nowakowski, 2018, Künstliche Photosynthese.

shouldbereplaced.Itshouldbeusedfurtherontoallocatepatientsto riskgroupsandtoreportclinicaltrialsinlymphomasasthereference.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011 .

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2009 .

Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

A. Rosenwald, M. Ziepert, N. Schmitz, 2020, Blood.

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

R. Spang, A. Rosenwald, M. Ziepert, 2019, Leukemia.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

C. Rübe, M. Ziepert, N. Schmitz, 2017, British journal of haematology.

Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma – analyses of cases from two prospective randomized clinical trials

A. Rosenwald, M. Ziepert, W. Klapper, 2009, Haematologica.

Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC

R. Spang, A. Rosenwald, W. Klapper, 2018, Leukemia & lymphoma.

Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2017 .

Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2018 .

Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2017 .

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

N. Schmitz, H. Döhner, M. Hallek, 2010 .

A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial

N. Schmitz, Sonali M. Smith, K. Savage, 2013 .

The best treatment for diffuse large B-cell lymphoma: a German perspective.

N. Schmitz, M. Pfreundschuh, R. Schmits, 2005, Oncology.

A NEW PROGNOSTIC MODEL TO ASSESS THE RISK OF CNS DISEASE IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2013 .

Aktuelle Standards in der Diagnostik und Therapie aggressiver B-Zell-Lymphome

N. Schmitz, G. Lenz, B. Friedrichs, 2020, DMW - Deutsche Medizinische Wochenschrift.

Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2014, Leukemia.

Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2012 .

Treatment of primary CNS lymphoma.

N. Schmitz, 2015, Blood.

Comment on Omuro et al , page 1403 Treatment of primary CNS lymphoma

N. Schmitz, 2015 .

Repetitive high-dose therapy followed by autologous stem cell transplantation (megachoep) for primary treatment of aggressive Nhl: the impact of rituximab on outcome and toxicity

N. Schmitz, L. Trümper, B. Metzner, 2006 .

Response: Intrathecal methotrexate and central nervous system events.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2009, Blood.

Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin.

N. Schmitz, H. Horst, R. Laufs, 1991, The New England journal of medicine.

Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report.

N. Schmitz, S. Montoto, P. Dreger, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT).

N. Schmitz, D. Linch, C. Kyriakou, 2004 .

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.

N. Schmitz, H. Heimpel, M. Griesshammer, 1996, Bone marrow transplantation.

Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.

V. Diehl, N. Schmitz, A. Ho, 2004 .

Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias.

N. Schmitz, M. Rister, J. Schaub, 1989, Bone Marrow Transplantation.

Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany

N. Schmitz, S. Günther, H. Frickmann, 2012, Infection.

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

N. Schmitz, I. Yakoub-Agha, P. Dreger, 2023, Leukemia.

Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany.

N. Schmitz, E. Thiel, A. Heinecke, 1987, Haematology and blood transfusion.

Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

N. Schmitz, W. Hiddemann, C. Buske, 2008 .

2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL

N. Schmitz, M. Pfreundschuh, L. Truemper, 2002 .

RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL

M. Ziepert, N. Schmitz, A. Buecker, 2017 .

DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT‐LWP STUDY

N. Schmitz, S. Montoto, P. Dreger, 2019, Hematological Oncology.

HuMax-CD4 (Zanolimumab), a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphoma of Non-Cutaneous Type.

N. Schmitz, F. d'Amore, J. Radford, 2005 .

Reply to A. Korfel et al.

N. Schmitz, M. Nickelsen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Precast commercial polyacrylamide gels for separation of DNA amplificates by temperature gradient gel electrophoresis: Application to clonality analysis of lymphomas

N. Schmitz, M. Tiemann, R. Parwaresch, 1996, Electrophoresis.

Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads.

N. Schmitz, P. Dreger, N. Neuhoff, 1995, Bone marrow transplantation.

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

N. Schmitz, S. Montoto, C. Gisselbrecht, 2009 .

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

J. Raemaekers, N. Schmitz, D. Niederwieser, 2016, Leukemia & lymphoma.

The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2008 .

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial

A. Rosenwald, M. Ziepert, N. Schmitz, 2023, HemaSphere.

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

A. Rosenwald, M. Ziepert, N. Schmitz, 2023, HemaSphere.

Influence of G-CSF on NK cell recovery after autologous BMT.

N. Schmitz, P. Dreger, H. Löffler, 1994, Bone Marrow Transplantation.

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

T. Lipp, N. Schmitz, A. Hüttmann, 2008 .

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2012 .

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2009 .

N. Schmitz, S. Kvaløy, H. Holte, 2001 .

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

N. Schmitz, P. Gaulard, C. Gisselbrecht, 2007 .

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, S. Wessendorf, 2006 .

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

A. Rosenwald, M. Ziepert, W. Klapper, 2016 .

Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia

C. Eberlein, N. Schmitz, H. Einsele, 2016 .

DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL

E. Kimby, N. Schmitz, S. Montoto, 2017 .

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

A. Rosenwald, M. Ziepert, T. Molina, 2023, Blood advances.

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

N. Schmitz, G. Lenz, R. Bouabdallah, 2020, Investigational New Drugs.

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

N. Schmitz, H. Döhner, M. Hallek, 2016 .

High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.

N. Schmitz, P. Dreger, B. Glass, 1996, Leukemia.

Rituximab in autologous stem cell transplantation for follicular lymphoma.

N. Schmitz, 2001, Anti-Cancer Drugs.

Reduced Intensity Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Is Associated with Substantial Late Transplant Related Mortality and a Poor Outcome in Patients with Chemoresistant Disease.

N. Schmitz, A. Sureda, S. Robinson, 2004 .

The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study.

N. Schmitz, H. Einsele, L. Kanz, 2007 .

Haploidentical ‘megadose’ stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings

N. Schmitz, M. Martelli, R. Mertelsmann, 2002, Leukemia.

N. Schmitz, C. Crawley, N. Russell, 2006 .

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

Granulocyte‐colony‐stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation

N. Schmitz, P. Dreger, V. Eckstein, 1993, British journal of haematology.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

A. Rosenwald, M. Ziepert, N. Schmitz, 2010, Blood.

Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.

N. Schmitz, P. Dreger, M. Michallet, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

N. Schmitz, H. Döhner, M. Hallek, 2010, Blood.

Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease: An analysis from the European group for Blood and Marrow Transplantation.

N. Schmitz, S. Mackinnon, A. Goldstone, 2002 .

Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial

N. Schmitz, H. Döhner, M. Hallek, 2017, British journal of haematology.

Allogeneic transplantation in T-cell lymphomas.

N. Schmitz, B. Glass, Huei-Shan Wu, 2014, Seminars in hematology.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

C. Rübe, M. Ziepert, N. Schmitz, 2014, Blood.

CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Developments and Quality Assurance in Stem Cell Transplantationfrom a German National Registry

N. Schmitz, A. Zander, C. Müller, 2006 .

[Therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and stem cell transplantation].

N. Schmitz, 1998, Praxis.

Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2005 .

Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).

M. Ziepert, N. Schmitz, G. Ott, 2020 .

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?

N. Schmitz, K. Savage, M. Nickelsen, 2016, Hematology/oncology clinics of North America.

Remission of juvenile chronic myeloid leukemia following graft failure of an unrelated marrow transplant and autologous recovery of marrow function promoted by GM-CSF and IL-3.

N. Schmitz, A. Ganser, W. Oster, 1991, Leukemia.

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

A. Rosenwald, M. Ziepert, W. Klapper, 2015, Leukemia.